Nautilus Biotechnology Inc (NAUT)
2.65
+0.08
(+3.11%)
USD |
NASDAQ |
Nov 05, 16:00
2.65
0.00 (0.00%)
After-Hours: 16:18
Nautilus Biotechnology Shareholders Equity (Quarterly): 223.43M for Sept. 30, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 223.43M |
| June 30, 2024 | 235.28M |
| March 31, 2024 | 249.49M |
| December 31, 2023 | 265.35M |
| September 30, 2023 | 277.27M |
| June 30, 2023 | 289.67M |
| March 31, 2023 | 303.72M |
| December 31, 2022 | 314.92M |
| Date | Value |
|---|---|
| September 30, 2022 | 325.34M |
| June 30, 2022 | 337.56M |
| March 31, 2022 | 349.71M |
| December 31, 2021 | 363.58M |
| September 30, 2021 | 377.85M |
| June 30, 2021 | 390.04M |
| December 31, 2020 | -29.72M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-29.72M
Minimum
Dec 2020
390.04M
Maximum
Jun 2021
284.90M
Average
303.72M
Median
Mar 2023
Shareholders Equity (Quarterly) Benchmarks
| Incyte Corp | 3.171B |
| Merck & Co Inc | 43.58B |
| Neogen Corp | 3.135B |
| Pfizer Inc | 87.70B |
| Repligen Corp | 1.986B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 259.70M |
| Total Liabilities (Quarterly) | 36.27M |